Amiloride Hydrochloride as an Effective Treatment for ADHD
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The investigators are proposing to test a medication derived from our prior studies of the
gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items,
which is impaired in ADHD and may cause an inability to plan, prioritize,
self-monitor,inhibit, initiate, self-correct, or control one's behavior. The investigators
now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride
hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in
medication-naïve adults with ADHD.
Phase:
Early Phase 1
Details
Lead Sponsor:
State University of New York - Upstate Medical University